We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $5.34B
1-Year Est. Return 380.18%
This Fund
S&P 500
This Quarter Est. Return
+21.59%
1 Year Est. Return
+380.18%
3 Year Est. Return
+803.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$852M
AUM Growth
+$102M
Cap. Flow
+$42.5M
Cap. Flow %
4.99%
Top 10 Hldgs %
62.79%
Holding
32
New
4
Increased
14
Reduced
5
Closed
9

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$36.9M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$27M
3
BIIB icon
Biogen
BIIB
+$23.8M
4
VOR icon
Vor Biopharma
VOR
+$23.4M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$22.8M

Top Sells

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$80.1M
2
AXSM icon
Axsome Therapeutics
AXSM
+$23.2M
3
ASND icon
Ascendis Pharma A/S
ASND
+$16.8M
4
ESPR
Esperion Therapeutics
ESPR
+$11.5M
5
MRUS
Merus
MRUS
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INCY icon
1
Incyte
INCY
$25.5B
$68.5M 8.04%
852,830
+79,748
+10% +$6.1M
BIIB icon
2
Biogen
BIIB
$31.1B
$66.1M 7.76%
238,772
+84,167
+54% +$23.8M
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$57.5M 6.74%
1,267,970
+417,585
+49% +$27M
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$54.3M 6.38%
477,585
+126,180
+36% +$10.5M
LEGN icon
5
Legend Biotech
LEGN
$3.87B
$52.7M 6.18%
1,054,870
-21,721
-2% -$1.05M
VRDN icon
6
Viridian Therapeutics
VRDN
$2.58B
$51.2M 6%
1,751,167
+114,956
+7% +$2.65M
SNDX icon
7
Syndax Pharmaceuticals
SNDX
$1.77B
$49.7M 5.84%
1,954,512
+869,370
+80% +$20.3M
IMCR icon
8
Immunocore
IMCR
$1.78B
$49M 5.75%
857,925
+84,846
+11% +$4.78M
ASND icon
9
Ascendis Pharma A/S
ASND
$17.1B
$43.1M 5.06%
352,808
-144,539
-29% -$16.8M
VOR icon
10
Vor Biopharma
VOR
$1.37B
$42.8M 5.03%
322,141
+236,959
+278% +$23.4M
UTHR icon
11
United Therapeutics
UTHR
$21.7B
$41.4M 4.86%
148,892
+8,331
+6% +$2.1M
SGEN
12
DELISTED
Seagen Inc. Common Stock
SGEN
$36.8M 4.32%
+286,288
New +$36.9M
BCYC
13
Bicycle Therapeutics
BCYC
$280M
$36.5M 4.29%
1,233,280
+74,594
+6% +$2M
ARGX icon
14
argenx
ARGX
$62.7B
$33.9M 3.98%
89,556
-741
-0.8% -$277K
AKRO
15
DELISTED
Akero Therapeutics
AKRO
$33.1M 3.89%
604,544
-228,721
-27% -$9.8M
ACLX
16
DELISTED
Arcellx
ACLX
$27.3M 3.21%
+882,101
New +$20.2M
KRTX
17
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$20.9M 2.45%
+106,210
New +$22.8M
ARVN icon
18
Arvinas
ARVN
$573M
$20.5M 2.41%
599,599
+315,822
+111% +$13.3M
ALPN
19
DELISTED
Alpine Immune Sciences Inc
ALPN
$17M 2%
2,317,634
+102,912
+5% +$658K
CRNX
20
DELISTED
Crinetics Pharmaceuticals
CRNX
$16.3M 1.91%
890,105
+370,849
+71% +$6.53M
ZLAB icon
21
Zai Lab
ZLAB
$2.82B
$15.8M 1.86%
+515,274
New +$16.3M
PSTX
22
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$12.9M 1.51%
2,434,816
+364,708
+18% +$1.67M
PRTA icon
23
Prothena Corp
PRTA
$477M
$4.52M 0.53%
75,000
-160,826
-68% -$9.42M
AXSM icon
24
Axsome Therapeutics
AXSM
$11B
– –
-520,080
Closed -$23.2M
BIIB icon
25
CALL
Biogen
BIIB
$31.1B
– –
-150,000
Closed -$40M
1
2

Similar funds

FFB
First Financial Bankshares Abilene, Texas $5.34B AUM 28.75% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $5.35B AUM 29.91% 1-Year Est. Return
IFG
Independent Financial Group San Diego, California $5.35B AUM 43.78% 1-Year Est. Return
CAU
Caxton Associates (UK) London $5.33B AUM 59.38% 1-Year Est. Return
CCWM
Cassaday & Co Wealth Management Mclean, Virginia $5.32B AUM 22.63% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $5.32B AUM 30.24% 1-Year Est. Return
Twin Tree Management
Twin Tree Management Dallas, Texas $5.31B AUM 55.82% 1-Year Est. Return

Paradigm Biocapital Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, Paradigm Biocapital Advisors held 32 positions worth $852M, up 14% from $750M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Paradigm Biocapital Advisors deployed $42.5M of net new capital in Q4 2022, opening 4 new positions and adding to 14 existing holdings. Its largest new stake was Seagen Inc. Common Stock: 286,288 shares worth $36.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $16.8M trimmed.

  • Paradigm Biocapital Advisors's largest Q4 2022 buy was Seagen Inc. Common Stock: 286,288 shares worth $36.8M.
  • Paradigm Biocapital Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q4 2022, an estimated $27M increase.
  • Paradigm Biocapital Advisors's biggest Q4 2022 reduction was Ascendis Pharma A/S, cutting an estimated $16.8M.
  • Paradigm Biocapital Advisors fully exited Global Blood Therapeutics, Inc. in Q4 2022, selling an estimated $80.1M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 63% of its $852M portfolio in Q4 2022.
  • Paradigm Biocapital Advisors opened 4 new positions and closed 9 in Q4 2022.
  • Paradigm Biocapital Advisors's portfolio value rose 14% quarter-over-quarter to $852M.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.